Robert Hershberg

Robert M.
Hershberg was the founder of VentiRx Pharmaceuticals, Inc., founded in 2006, where the titles held included President, Chief Executive Officer & Director from 2012 to 2017.
Dr. Hershberg is the founder of HilleVax, Inc., founded in 2020, holding the title of President.
Dr. Hershberg is the founder of Cajal Therapeutics, founded in 2020, serving as Executive Chairman since 2020.
Current jobs include Vice Chairman at Recursion Pharmaceuticals, Inc. since 2019, Independent Director at Adaptive Biotechnologies Corp.
since 2013, Senior Advisor at Frazier Management LLC since 2020, Member at UW Medicine, Director at Beckley Psytech Ltd. since 2024, Independent Director at Atai Beckley, Inc. since 2025.
Former jobs include Independent Director at NS Wind Down Co., Inc. from 2015 to 2022, Independent Director at Silverback Therapeutics, Inc. from 2017 to 2022, Independent Director at Fate Therapeutics, Inc. from 2020 to 2024, Director at Guide Therapeutics, Inc., Non-Executive Director at Atai Beckley NV, Vice President-Medical Genetics at Corixa Corp.
from 2001 to 2003, Chief Medical Officer & Senior Vice President at Dendreon Corp.
from 2003 to 2006, Assistant Professor at Harvard Medical School, Chief Scientific Officer & Executive VP at Celgene Corp.
from 2017 to 2020.
Education includes a doctorate from The Salk Institute for Biological Studies and both undergraduate and doctorate degrees from the University of California, Los Angeles.